SCHEMBL20918487

SCHEMBL20918487

COc1cc(N)ncc1C(=O)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 0.44
GABRD O14764 3/20 0.44
GABRA1 P14867 3/20 0.44
GABRB1 P18505 3/20 0.44
GABRG2 P18507 3/20 0.44
GABRB3 P28472 3/20 0.44
GABRA5 P31644 3/20 0.44
GABRA3 P34903 3/20 0.44
GABRA2 P47869 3/20 0.44
GABRB2 P47870 3/20 0.44
GABRA4 P48169 3/20 0.44
GABRE P78334 3/20 0.44
GABRA6 Q16445 3/20 0.44
GABRG1 Q8N1C3 3/20 0.44
GABRG3 Q99928 3/20 0.44
GABRQ Q9UN88 3/20 0.44
LRRK2 Q5S007 2/20 0.42
MAP4K1 Q92918 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NUDT1 P36639 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20935057 0.82 MEN1 (0.43) LRRK2MAP4K1NUDT1PDE9APOLQ
SCHEMBL20918679 0.81 LRRK2 (0.47) LRRK2ALDH1A1NUDT1PDE9APOLQ
SCHEMBL18361719 0.81 LRRK2 (0.42) LRRK2MAP4K1ALDH1A1NUDT1PDE9A
SCHEMBL3303055 0.80 KDM4E (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9793706 0.76 KDM4E (0.49) LRRK2MAP4K1ALDH1A1KDM4EGAA
SCHEMBL23510739 0.75 GABRP (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14376019 0.73 CYP3A4 (0.57) LRRK2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL8828646 0.73 KDM4E (0.62) MAP4K1ALDH1A1KDM4EGAA
SCHEMBL31216654 0.71 KDM4E (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL20918596 0.71 GSK3B (0.41) LRRK2ALDH1A1NUDT1KDM4EPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 US disclosed
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 US disclosed
EP-3697772-A1 PYRIMIDINE TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2020-08-26 EP disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF DTYMK, TBKBP1, NFKBIA GABRP 2092/4885GABRD 2255/4885GABRA1 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.